SPONTAN Phase II Final Results
Filed with ASX · · 4 pages · English
Summary by 6ix AI
LTR Pharma Limited has released the final Clinical Study Report for the SPONTAN Phase II pharmacokinetic study, confirming significant findings regarding absorption rates and safety profiles. The report indicates that SPONTAN achieves a notably faster absorption rate compared to traditional oral tablets, completing the pharmacokinetic dataset required for FDA submission. The study involved healthy adult males and demonstrated no serious adverse events, supporting the product's favorable safety profile. Next steps include preparations for a pivotal Phase III study and further engagement with potential U.S. licensing partners.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Earlier from LTR Pharma
- FY26 Results Announcement
- SPONTAN Real-World Study Reports 93% Response
- LTR Executes U.S. Commercial Agreement with Strive
- LTR Executes Definitive U.S. Commercial Agreement with Shed
- Response to ASX Aware Letter
Later from LTR Pharma
- First ROXUS Prescriptions Fulfilled in the United States
- Australian-Developed ED Nasal Spray Now Being Prescribed in the U.S.
- Quarterly Activities/Appendix 4C Cash Flow Report
Follow LTR Pharma into a list and get an email when it puts out news.
Follow LTR Pharma